Search
Fursultiamine
go.drugbank.com/drugs/DB08966ApprovedCompound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Mixtures: ALINAMIN EX PLUSSulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Mixtures: AMPICILLINA E SULBACTAM IBI, AMPICILLINA E SULBACTAM IBIDoxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalIt is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair.
Memantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalInitially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million.
Categories: N-methyl-D-aspartate Receptor AntagonistPidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729]. … exercising caution in their recommendation as much more research is necessary [A32981, A32982].
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923] … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
Rurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalIt was first approved by the European Commission in January 2018. … Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.
Thonzonium
go.drugbank.com/drugs/DB09552ApprovedIt is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication.